Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oncternal Therapeutics, Inc. - Common Stock (NQ: ONCT )

0.5266 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Oncternal Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
23 Stocks Moving in Thursday's Pre-Market Session
Gainers Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) rose 54.3% to $0.9490 in pre-market trading after declining more than 11% on Wednesday. Alterity Therapeutics Limited... 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Annexon Announces Mixed Phase 2 Data From Huntington Disease Trial Annexon,... 
Via Benzinga
21 Stocks Moving in Wednesday's Pre-Market Session
Gainers Wejo Group Ltd (NASDAQ: WEJO) rose 37% to $8.63 in pre-market trading after the company announced a new connected vehicle platform with Microsoft, called Wejo Neural Edge... 
Via Benzinga
Analyzing Oncternal Therapeutics's Unusual Options Activity
On Friday, shares of Oncternal Therapeutics (NASDAQ:ONCT) ... 
Via Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
Analyzing The Price Action In Oncternal Therapeutics Stock Today
Oncternal Therapeutics's Stock Price And Volume Action Oncternal Therapeutics's (NASDAQ: 
Via Benzinga
Oncternal, FDA In Pact For Pivotal Study Design For Zilovertam In Mantle Cell Lymphoma
The FDA and Oncternal Therapeutics Inc (NASDAQ: ONCT) have agreed on key elements of the Company's Phase 3 trial of zilovertamab for relapsed or refractory... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Oncternal Therapeutics (NASDAQ:ONCT 
Via Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
Oncternal Therapeutics, Inc. (ONCT) Q3 2021 Earnings Call Transcript
ONCT earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Return on Capital Employed Overview: Oncternal Therapeutics
Benzinga Pro data, Oncternal Therapeutics (NASDAQ:ONCT) reported Q2 sales of $883.00 thousand. Earnings fell to a loss of $7.69 million, resulting in a 29.05% decrease from last... 
Via Benzinga
Oncternal Therapeutics, Inc. (ONCT) Q2 2021 Earnings Call Transcript
ONCT earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Recap: Oncternal Therapeutics Q2 Earnings
Shares of Oncternal Therapeutics (NASDAQ:ONCT) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 52.94% over... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Galectin Therapeutics (NASDAQ:GALT) shares moved upwards by 47.46% to $4.07 during Friday's pre-market session. The market value of their outstanding shares is... 
Via Benzinga
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,... 
Via Benzinga
Exposures Product Safety
Oncternal Shares Jump After Encouraging Early Action In Soft-Tissue Sarcoma Trial With TK216
Oncternal Therapeutics Inc (NASDAQ: ONCT) has announced updated interim clinical data from its ongoing Phase 1/2 trial evaluating TK216 in relapsed or refractory... 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 19) ESSA Pharma Inc. (NASDAQ:... 
Via Benzinga
Exposures COVID-19
20 Stocks Moving in Thursday's Pre-Market Session
Gainers PDS Biotechnology Corporation (NASDAQ: PDSB) rose 18% to $6.77 in pre-market trading as traders circulated abstract from American Society Of Clinical Oncology website.... 
Via Benzinga
Oncternal Therapeutics, Inc. (ONCT) Q1 2021 Earnings Call Transcript
ONCT earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
42 Stocks Moving In Monday's Mid-Day Session
Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares jumped 44.8% to $8.05 after the company's 13D filing showed that Modell's Sporting Goods had reported a stake... 
Via Benzinga
55 Biggest Movers From Yesterday
Gainers Celcuity Inc. (NASDAQ: CELC) jumped 29.4% to settle at $27.94. Celcuity shares climbed 51% on Friday after the company announced a worldwide licensing agreement with... 
Via Benzinga
38 Stocks Moving In Friday's Mid-Day Session
Gainers Celcuity Inc. (NASDAQ: CELC) shares jumped 64.5% to $23.54 after the company announced a worldwide licensing agreement with Pfizer to develop and commercialize... 
Via Benzinga
51 Biggest Movers From Friday
Gainers Celcuity Inc. (NASDAQ: CELC) shares climbed 50.9% to close at $21.60 on Friday after the company announced a worldwide licensing agreement with Pfizer to develop and... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Greenwich LifeSciences (NASDAQ:GLSI) stock moved upwards by 32.67% to $67.0 during Friday's pre-market session. The company's market cap stands at $860.7... 
Via Benzinga
The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 7) Aclaris Therapeutics, Inc... 
Via Benzinga
Exposures Product Safety
Why Oncternal Therapeutics Stock Is Popping Today
This analyst is excited about the company's prospects. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For April 7, 2021
Upgrades According to Janney Capital, the prior rating for Texas Capital Bancshares Inc (NASDAQ:TCBI) was changed from Neutral to Buy. Texas Capital Bancshares earned $1.... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.